Drugs / DB-2304
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06625671 | Oct 2024 → Jun 2027 expected | lupus erythematosus | DualityBio Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-11-24 | DualityBio Inc. | Results Duality Biologics Orally Presents Phase 1 Healthy Volunteer Data for First-in-Class BDCA2-Targeted ADC DB-2304 at Autumn Immunology Conference 2025 dualitybiologics.com ↗
Results demonstrated that DB-2304 was generally safe and well-tolerated in healthy participants, showed approximately linear pharmacokinetics (PK), and effectively reached and engaged the intended target, validating its pharmacological mechanism. |
| 2024-11-04 | DualityBio Inc. | Regulatory DualityBio's First-in-Class ADC Drug DB-2304 for Autoimmune Diseases Completes First Global Patient Dosing in Phase I Clinical Trial dualitybiologics.com ↗
DB-2304, the first-in-class BDCA2 ADC drug targeting autoimmune diseases, developed based on its proprietary DIMAC platform and holding global patents, has received Clinical Trial Notification (CTN) approval from Australia's Therapeutic Goods Administration (TGA) and completed the first global patient dosing. |
All press releases naming this drug 3 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DB-2304 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06625671 ↗ |